Amgen pays Nektar $50M for polymer

The cancer drug developer Nektar Therapeutics ($NKTR) has inked a deal to supply a proprietary polymer to Amgen ($AMGN) for $50 million. And in the event it fails to deliver the polymer as contracted, Amgen gains the right of access to the manufacturing facility. Nektar also stands to earn more from the deal if Amgen ups its order. Report

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.